The incretins Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which were suggested to be efficacy in restoring insulin sensitivity (53), have shown potential in reducing GV in patients with Type 2 Diabetes (54, 55). The gene discussed is INS; the disease is type 2 diabetes mellitus.